Ani Pharmaceutic Financials
This page shows Ani Pharmaceutic (ANIP) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 17 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores
Ani Pharmaceutic has an operating margin of 12.6%, meaning the company retains $13 of operating profit per $100 of revenue. This results in a moderate score of 50/100, indicating healthy but not exceptional operating efficiency. This is up from 0.1% the prior year.
Ani Pharmaceutic's revenue surged 43.8% year-over-year to $883.4M, reflecting rapid business expansion. This strong growth earns a score of 100/100.
Ani Pharmaceutic carries a low D/E ratio of 0.54, meaning only $0.54 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 91/100, indicating a strong balance sheet with room for future borrowing.
Ani Pharmaceutic's current ratio of 2.71 indicates adequate short-term liquidity, earning a score of 51/100. The company can meet its near-term obligations, though with limited headroom.
Ani Pharmaceutic converts 19.4% of revenue into free cash flow ($171.4M). This strong cash generation earns a score of 74/100.
Ani Pharmaceutic's ROE of 14.5% shows moderate profitability relative to equity, earning a score of 43/100. This is up from -4.6% the prior year.
Ani Pharmaceutic scores 2.35, placing it in the grey zone between 1.81 and 2.99. This signals moderate financial risk that warrants monitoring.
Ani Pharmaceutic passes 7 of 9 financial strength tests. All 4 profitability signals pass (positive income, cash flow, and earnings quality), 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, Ani Pharmaceutic generates $2.36 in operating cash flow ($185.2M OCF vs $78.3M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
Ani Pharmaceutic earns $3.4 in operating income for every $1 of interest expense ($111.1M vs $32.6M). This adequate coverage means the company can meet its interest obligations, but has limited cushion if earnings fall.
Key Financial Metrics
Earnings & Revenue
Ani Pharmaceutic generated $883.4M in revenue in fiscal year 2025. This represents an increase of 43.8% from the prior year.
Ani Pharmaceutic's EBITDA was $202.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 196.4% from the prior year.
Ani Pharmaceutic reported $78.3M in net income in fiscal year 2025. This represents an increase of 522.9% from the prior year.
Ani Pharmaceutic earned $3.32 per diluted share (EPS) in fiscal year 2025. This represents an increase of 419.2% from the prior year.
Cash & Balance Sheet
Ani Pharmaceutic generated $171.4M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 258.7% from the prior year.
Ani Pharmaceutic held $285.6M in cash against $291.8M in long-term debt as of fiscal year 2025.
Ani Pharmaceutic had 22M shares outstanding in fiscal year 2025. This represents an increase of 6.6% from the prior year.
Margins & Returns
Ani Pharmaceutic's gross margin was 61.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 2.1 percentage points from the prior year.
Ani Pharmaceutic's operating margin was 12.6% in fiscal year 2025, reflecting core business profitability. This is up 12.5 percentage points from the prior year.
Ani Pharmaceutic's net profit margin was 8.9% in fiscal year 2025, showing the share of revenue converted to profit. This is up 11.9 percentage points from the prior year.
Ani Pharmaceutic's ROE was 14.5% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 19.1 percentage points from the prior year.
Capital Allocation
Ani Pharmaceutic invested $51.7M in research and development in fiscal year 2025. This represents an increase of 15.9% from the prior year.
Ani Pharmaceutic spent $12.2M on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding. This represents an increase of 11.4% from the prior year.
Ani Pharmaceutic invested $13.8M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 14.8% from the prior year.
ANIP Income Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $247.1M+8.4% | $227.8M+7.8% | $211.4M+7.2% | $197.1M+3.4% | $190.6M+28.5% | $148.3M+7.5% | $138.0M+0.4% | $137.4M |
| Cost of Revenue | $100.3M+7.4% | $93.4M+25.2% | $74.6M+2.2% | $73.0M-9.0% | $80.3M+27.3% | $63.1M+9.3% | $57.7M+17.4% | $49.2M |
| Gross Profit | $146.8M+9.2% | $134.4M-1.7% | $136.8M+10.2% | $124.1M+12.5% | $110.3M+29.4% | $85.3M+6.1% | $80.3M-9.0% | $88.3M |
| R&D Expenses | $12.3M-0.3% | $12.3M-25.6% | $16.5M+56.5% | $10.6M-36.5% | $16.6M+64.4% | $10.1M+38.8% | $7.3M-30.6% | $10.5M |
| SG&A Expenses | $82.8M+8.0% | $76.7M-6.3% | $81.8M+6.9% | $76.5M+9.8% | $69.7M-11.8% | $79.1M+49.7% | $52.8M+10.0% | $48.0M |
| Operating Income | $34.8M-4.1% | $36.2M+160.9% | $13.9M-47.0% | $26.2M+698.3% | -$4.4M+78.7% | -$20.5M-497.0% | $5.2M-74.6% | $20.3M |
| Interest Expense | $8.0M-3.9% | $8.3M+0.7% | $8.2M+1.4% | $8.1M-7.9% | $8.8M+32.1% | $6.7M-26.6% | $9.1M-0.4% | $9.1M |
| Income Tax | $4.0M-44.5% | $7.2M+263.5% | $2.0M-54.1% | $4.3M+223.5% | -$3.5M+52.5% | -$7.3M | $0-100.0% | $7.1M |
| Net Income | $27.5M+3.3% | $26.6M+211.3% | $8.5M-45.5% | $15.7M+252.6% | -$10.3M+57.5% | -$24.2M-956.7% | -$2.3M-112.6% | $18.2M |
| EPS (Diluted) | N/A | $1.13+213.9% | $0.36-47.8% | $0.69 | N/A | $-1.27-807.1% | $-0.14-117.1% | $0.82 |
ANIP Balance Sheet
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.4B+2.3% | $1.4B+4.9% | $1.3B+3.9% | $1.3B+0.6% | $1.3B-0.2% | $1.3B+39.8% | $920.8M+0.7% | $914.5M |
| Current Assets | $753.1M+7.8% | $698.4M+15.9% | $602.6M+12.4% | $536.3M+1.5% | $528.5M+1.4% | $521.3M-6.2% | $555.5M+2.8% | $540.6M |
| Cash & Equivalents | $285.6M+8.7% | $262.6M+20.6% | $217.8M+45.4% | $149.8M+3.4% | $144.9M-0.1% | $145.0M-39.6% | $240.1M+5.0% | $228.6M |
| Inventory | $143.1M-2.3% | $146.5M+5.9% | $138.3M+0.7% | $137.4M+0.5% | $136.8M-7.6% | $148.0M+18.0% | $125.4M+10.2% | $113.8M |
| Accounts Receivable | $281.1M+11.3% | $252.6M+11.9% | $225.7M+2.4% | $220.3M-0.6% | $221.7M+12.9% | $196.4M+18.2% | $166.1M-3.7% | $172.4M |
| Goodwill | $62.5M0.0% | $62.5M+3.2% | $60.5M-0.2% | $60.7M+1.1% | $60.0M-0.7% | $60.4M+114.1% | $28.2M0.0% | $28.2M |
| Total Liabilities | $899.7M-0.3% | $902.3M+2.4% | $881.4M+3.8% | $849.0M-0.8% | $855.9M-0.1% | $856.6M+94.6% | $440.1M+0.6% | $437.7M |
| Current Liabilities | $278.1M+2.8% | $270.6M+14.2% | $236.8M+17.4% | $201.8M+3.8% | $194.5M+2.4% | $189.9M+35.7% | $140.0M+2.3% | $136.9M |
| Long-Term Debt | $291.8M-2.0% | $297.7M-1.3% | $301.5M-1.2% | $305.3M-1.2% | $309.1M-1.2% | $312.9M+10.0% | $284.4M-0.1% | $284.6M |
| Total Equity | $540.7M+6.9% | $505.8M+15.8% | $436.8M+4.3% | $418.6M+3.7% | $403.7M-0.6% | $405.9M-10.9% | $455.8M+0.8% | $452.0M |
| Retained Earnings | -$23.1M+54.3% | -$50.6M+34.2% | -$76.9M+9.6% | -$85.0M+15.2% | -$100.3M-11.9% | -$89.6M-37.8% | -$65.0M-4.3% | -$62.3M |
ANIP Cash Flow Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $30.4M-31.1% | $44.1M-41.9% | $75.8M+116.7% | $35.0M+120.6% | $15.9M+27.1% | $12.5M-28.4% | $17.4M-4.7% | $18.3M |
| Capital Expenditures | $1.2M-79.6% | $6.1M+52.0% | $4.0M+62.2% | $2.5M+3.3% | $2.4M-50.2% | $4.8M+8.2% | $4.4M-2.9% | $4.6M |
| Free Cash Flow | $29.1M-23.3% | $38.0M-47.1% | $71.8M+120.8% | $32.5M+141.5% | $13.5M+75.8% | $7.7M-40.9% | $13.0M-5.3% | $13.7M |
| Investing Cash Flow | -$1.4M+77.2% | -$6.2M+10.8% | -$6.9M+65.2% | -$19.8M-85.8% | -$10.7M+97.3% | -$398.5M-8857.6% | -$4.4M-149.8% | $8.9M |
| Financing Cash Flow | -$4.6M-173.1% | $6.3M+463.2% | -$1.7M+82.4% | -$9.9M-101.9% | -$4.9M-101.7% | $291.0M+20143.4% | -$1.5M+92.6% | -$19.7M |
| Dividends Paid | $0-100.0% | $344K-15.5% | $407K+0.2% | $406K0.0% | $406K0.0% | $406K-0.2% | $407K+0.2% | $406K |
| Share Buybacks | $611K-41.5% | $1.0M+89.5% | $551K-94.5% | $10.0M+3045.6% | $318K-53.2% | $680K-47.7% | $1.3M-85.0% | $8.7M |
ANIP Financial Ratios
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 59.4%+0.4pp | 59.0%-5.7pp | 64.7%+1.8pp | 62.9%+5.1pp | 57.9%+0.4pp | 57.5%-0.7pp | 58.2%-6.0pp | 64.2% |
| Operating Margin | 14.1%-1.8pp | 15.9%+9.3pp | 6.6%-6.7pp | 13.3%+15.6pp | -2.3%+11.5pp | -13.8%-17.6pp | 3.7%-11.0pp | 14.8% |
| Net Margin | 11.1%-0.6pp | 11.7%+7.6pp | 4.0%-3.9pp | 8.0%+13.3pp | -5.4%+10.9pp | -16.3%-14.6pp | -1.7%-14.9pp | 13.3% |
| Return on Equity | 5.1%-0.2pp | 5.3%+3.3pp | 2.0%-1.8pp | 3.8%+6.3pp | -2.5%+3.4pp | -5.9%-5.5pp | -0.5%-4.5pp | 4.0% |
| Return on Assets | 1.9%+0.0pp | 1.9%+1.3pp | 0.6%-0.6pp | 1.2%+2.0pp | -0.8%+1.1pp | -1.9%-1.6pp | -0.3%-2.2pp | 2.0% |
| Current Ratio | 2.71+0.1 | 2.58+0.0 | 2.54-0.1 | 2.66-0.1 | 2.72-0.0 | 2.74-1.2 | 3.97+0.0 | 3.95 |
| Debt-to-Equity | 0.54-0.0 | 0.59-0.1 | 0.69-0.0 | 0.73-0.0 | 0.770.0 | 0.77+0.1 | 0.620.0 | 0.63 |
| FCF Margin | 11.8%-4.9pp | 16.7%-17.3pp | 34.0%+17.5pp | 16.5%+9.4pp | 7.1%+1.9pp | 5.2%-4.2pp | 9.4%-0.6pp | 10.0% |
Similar Companies
Frequently Asked Questions
What is Ani Pharmaceutic's annual revenue?
Ani Pharmaceutic (ANIP) reported $883.4M in total revenue for fiscal year 2025. This represents a 43.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Ani Pharmaceutic's revenue growing?
Ani Pharmaceutic (ANIP) revenue grew by 43.8% year-over-year, from $614.4M to $883.4M in fiscal year 2025.
Is Ani Pharmaceutic profitable?
Yes, Ani Pharmaceutic (ANIP) reported a net income of $78.3M in fiscal year 2025, with a net profit margin of 8.9%.
What is Ani Pharmaceutic's EBITDA?
Ani Pharmaceutic (ANIP) had EBITDA of $202.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Ani Pharmaceutic have?
As of fiscal year 2025, Ani Pharmaceutic (ANIP) had $285.6M in cash and equivalents against $291.8M in long-term debt.
What is Ani Pharmaceutic's gross margin?
Ani Pharmaceutic (ANIP) had a gross margin of 61.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Ani Pharmaceutic's operating margin?
Ani Pharmaceutic (ANIP) had an operating margin of 12.6% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Ani Pharmaceutic's net profit margin?
Ani Pharmaceutic (ANIP) had a net profit margin of 8.9% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Ani Pharmaceutic's return on equity (ROE)?
Ani Pharmaceutic (ANIP) has a return on equity of 14.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Ani Pharmaceutic's free cash flow?
Ani Pharmaceutic (ANIP) generated $171.4M in free cash flow during fiscal year 2025. This represents a 258.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Ani Pharmaceutic's operating cash flow?
Ani Pharmaceutic (ANIP) generated $185.2M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Ani Pharmaceutic's total assets?
Ani Pharmaceutic (ANIP) had $1.4B in total assets as of fiscal year 2025, including both current and long-term assets.
What are Ani Pharmaceutic's capital expenditures?
Ani Pharmaceutic (ANIP) invested $13.8M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Ani Pharmaceutic spend on research and development?
Ani Pharmaceutic (ANIP) invested $51.7M in research and development during fiscal year 2025.
What is Ani Pharmaceutic's current ratio?
Ani Pharmaceutic (ANIP) had a current ratio of 2.71 as of fiscal year 2025, which is generally considered healthy.
What is Ani Pharmaceutic's debt-to-equity ratio?
Ani Pharmaceutic (ANIP) had a debt-to-equity ratio of 0.54 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Ani Pharmaceutic's return on assets (ROA)?
Ani Pharmaceutic (ANIP) had a return on assets of 5.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Ani Pharmaceutic's Altman Z-Score?
Ani Pharmaceutic (ANIP) has an Altman Z-Score of 2.35, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Ani Pharmaceutic's Piotroski F-Score?
Ani Pharmaceutic (ANIP) has a Piotroski F-Score of 7 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Ani Pharmaceutic's earnings high quality?
Ani Pharmaceutic (ANIP) has an earnings quality ratio of 2.36x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Ani Pharmaceutic cover its interest payments?
Ani Pharmaceutic (ANIP) has an interest coverage ratio of 3.4x, meaning it can adequately cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Ani Pharmaceutic?
Ani Pharmaceutic (ANIP) scores 68 out of 100 on our Financial Profile, indicating strong overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.